Amicus Therapeutics Inc

Amicus Therapeutics — 40th Annual J.P. Morgan Healthcare Conference 2022

29 slides from Amicus Therapeutics's conference presentation, Jan 10, 2022

  1. Slide 1: At the Forefront of Therapies for Rare Diseases

    Slide 1: At the Forefront of Therapies for Rare Diseases

    40th Annual J.P. Morgan Healthcare Conference January 12, 2022 At the Forefront of Therapies for Rare Diseases

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: Our Passion is for Patients: Mission and Vision

    Slide 3: Our Passion is for Patients: Mission and Vision

    3 Amicus Definition: \əˈmēkəs (noun) Latin Friend Our Passion is for Patients Our Mission: We seek to deliver the highest quality therapies for people living with rare diseases Our Vision: Be a leader in rare disease drug development and commercialization leveraging our expertise in bringing life-ch

  4. Slide 4: A Rare Company

    Slide 4: A Rare Company

    4 A Rare Company Leading, Patient Dedicated, Rare Disease Biotechnology Company with Sustained Double-Digit Revenue Growth, a Global Commercial Infrastructure, and Late-stage Development Capabilities Gene Therapy PLATFORM Protein Engineering & Glycobiology $557M Cash as of 9/30/21 AT-GAA a Two-Compo

  5. Slide 5: 2021 Strategic Priorities Accomplished

    Slide 5: 2021 Strategic Priorities Accomplished

    2021 Strategic Priorities Accomplished: Setting the Stage for a Successful 2022 1 2 3 4 5 Achieve double-digit Galafold growth and revenue of $300M to $315M Report data from the AT-GAA Phase 3 PROPEL study and complete BLA and MAA filings for regulatory approvals Advance clinical studies, regulatory

  6. Slide 6: 2022 Strategic Priorities to Drive Value

    Slide 6: 2022 Strategic Priorities to Drive Value

    2022 Strategic Priorities to Drive Value 1 2 3 4 5 Continued double-digit Galafold growth (15-20%) with revenue of $350M to $365M Secure FDA approval and positive CHMP opinion for AT-GAA Initiate successful, rapid launch in U.S. for AT-GAA Advance best-in-class next-generation genetic medicines and

  7. Slide 7: Amicus Pipeline

    Slide 7: Amicus Pipeline

    7 INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold®(migalastat) Fabry Gene Therapy POMPE FRANCHISE AT-GAA (cipaglucosidase alfa + miglustat) Pompe Gene Therapy NEXT- GENERATION RESEARCH PROGRAMS Multiple programs* Amicus Pipeline Streamlined Rare Dise

  8. Slide 8: Positioned for Significant Value Growth

    Slide 8: Positioned for Significant Value Growth

    8 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double-Digit Revenue Growth on Path to Profitability Continue to bring Galafold to as many patients as possible, sustain double digit revenue growth Successful launch of AT-GAA for people living with Pompe disease

  9. Slide 9: Galafold (migalastat) Continued Growth

    Slide 9: Galafold (migalastat) Continued Growth

    9 Galafold® (migalastat) Continued Growth... … building a leadership position in the treatment of Fabry disease

  10. Slide 10: Fabry Disease Overview

    Slide 10: Fabry Disease Overview

    10 Fabry Disease Overview .. Deficiency of α-Gal A enzyme leading to GL-3 accumulation .. 1,000+ known mutations .. 13,000+ diagnosed WW (51% female/49% male4) Fabry is a rare inherited genetic disorder caused by the deficiency of the GLA enzyme Leading Causes of Death Life-Limiting Symptoms TRANSIE

  11. Slide 11: Global Fabry Market

    Slide 11: Global Fabry Market

    11 Global Fabry Market .. Fabry Disease is believed to be significantly underdiagnosed – Newborn screening studies suggest Fabry could be one of the more prevalent human genetic diseases (~1:1,000 to ~1:4,000) .. In 2021, Galafold was the fastest growing medicine for Fabry disease and the greatest c

  12. Slide 12: 2021 Galafold Success

    Slide 12: 2021 Galafold Success

    12 2021 Galafold Success Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse reactions reported with Galafold (≥10%) were headache, na

  13. Slide 13: Key Performance Indicators Lay the Groundwork for 2022

    Slide 13: Key Performance Indicators Lay the Groundwork for 2022

    13 Key Performance Indicators Lay the Groundwork for 2022 .. Hybrid business model (virtual/in-person) surpassed pre-COVID physician interactions .. Achieved estimated 49%+ global share of treated amenable patients .. Multiple new markets opened in 2021 .. Global mix of switch (~55%) and previously

  14. Slide 14: Galafold Growth Opportunity

    Slide 14: Galafold Growth Opportunity

    14 Penetration of diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong intellectual property rights Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opportunity $1B Annual Sales Opportunity at Pe

  15. Slide 15: Global Commercial Infrastructure

    Slide 15: Global Commercial Infrastructure

    15 - 43 countries with approvals - 35 countries reimbursed sales - Presence in 43 countries Experienced Global Commercial Team Global Commercial Infrastructure Highly Leverageable to Ensure Strong Global Launch of AT-GAA Galafold approvals in 40+ countries and commercial sales in 30+ of those today

  16. Slide 16: AT-GAA (cipaglucosidase alfa + miglustat)

    Slide 16: AT-GAA (cipaglucosidase alfa + miglustat)

    16 AT-GAA (cipaglucosidase alfa + miglustat) … potential to establish a new standard of care for people living with Pompe disease

  17. Slide 17: Pompe Disease Overview

    Slide 17: Pompe Disease Overview

    17 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality 5,000 – 10,00

  18. Slide 18: Global Pompe Market

    Slide 18: Global Pompe Market

    18 Global Pompe Market Global Pompe Disease Market Growth Continues to be Driven by the Diagnosis of New Patients, Only One Approved Therapy on the Market up until 2021 .. Pompe Disease believed to be significantly underdiagnosed – Newborn screening studies suggests Pompe to be more prevalent than m

  19. Slide 19: AT-GAA: An Innovative Approach to Pompe Disease

    Slide 19: AT-GAA: An Innovative Approach to Pompe Disease

    19 AT-GAA: An Innovative Approach to Pompe Disease Our Scientists Created a Uniquely Glycosylated and Highly Phosphorylated ERT (ATB200) that Significantly Enhances Targeting to Key Affected Muscles .. AT-GAA is a two-component therapy combining ATB200, an ERT, with AT2221, an orally administered en

  20. Slide 20: Clinically Meaningful Outcomes from Phase 3 PROPEL Study

    Slide 20: Clinically Meaningful Outcomes from Phase 3 PROPEL Study

    20 Phase 3 PROPEL Study Clinically Meaningful Outcomes from Phase 3 PROPEL Study Provide the Basis for Global Regulatory Submissions of AT-GAA .. Peer-reviewed results from PROPEL suggest that treatment with AT-GAA provided clinically meaningful improvements over standard of care, including ERT-expe

  21. Slide 21: PROPEL Study Results

    Slide 21: PROPEL Study Results

    21 Phase 3 PROPEL Study Results Endpoints Across Motor Function, Pulmonary Function, Muscle Strength, Pros, and Biomarkers Favored AT-GAA over Alglucosidase Alfa

  22. Slide 22: AT-GAA: Key Takeaways

    Slide 22: AT-GAA: Key Takeaways

    22 AT-GAA: Key Takeaways .. Regulatory status update: – U.S. PDUFA date mid 20221 – CHMP opinion late 2022 – Planning for additional regulatory submissions .. Multiple early access mechanisms in place, including U.K., Germany, Japan, and others .. 150+ people living with Pompe disease are on AT-GAA

  23. Slide 23: Launch Preparations

    Slide 23: Launch Preparations

    23 Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease centers Development of educational materials Planning Access Edu

  24. Slide 24: Financial Summary

    Slide 24: Financial Summary

    24 Financial Summary … maintaining a strong financial outlook

  25. Slide 25: Transforming for the Future

    Slide 25: Transforming for the Future

    25 Transforming for the Future We remain a global, patient-dedicated biotechnology company developing and delivering novel high-quality medicines for people living with rare diseases Focus will be to grow our leadership position across our two lead indications of Fabry disease and Pompe disease: – C

  26. Slide 26: Financial Outlook and Path to Profitability

    Slide 26: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear Strategy to Build our Business, Advance our Portfolio, and Achieve Profitability 1Preliminary and unaudited 26 Drive Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $306M1 full-year 2021 revenue 2022 Galafold revenue guidance of

  27. Slide 27: Expanding Our Leadership Position in Fabry and Pompe

    Slide 27: Expanding Our Leadership Position in Fabry and Pompe

    27 Expanding Our Leadership Position in Fabry and Pompe Differentiated Gene Therapy Approach for Greater Potency and Optimized Cross Correction through Transgene Engineering for Stability and Targeting Fabry Gene Therapy Pompe Gene Therapy .. Proprietary AAV capsid .. Pantropic capsid and ubiquitous

  28. Slide 28: True Measure of Success: Impacting Patients' Lives

    Slide 28: True Measure of Success: Impacting Patients' Lives

    28 True Measure of Success: Impacting the Lives of Patients Living with Rare Diseases YE17 2023+ Thousands of Patients* >1,900+ Patients* YE21 >350 Patients* *Clinical & commercial, all figures approximate

  29. Slide 29: Thank You

    Slide 29: Thank You

    Thank You

Source: SEC EDGAR · 8-K filed Jan 10, 2022

More decks from Amicus Therapeutics Inc